美国退伍军人事务医疗系统感染发病率与抗菌药物耐药趋势:2007-22年全国回顾性队列研究
该全国回顾性队列研究分析2007年2月1日至2022年3月31日美国138家退伍军人事务医疗中心全部急症住院患者的临床微生物数据,共收集507760例患者的991527株30天 incident 分离株,采用广义估计方程报告年均百分比变化(AAPC)。研究期间多种病原体及病原-药物组合的感染发病率与耐药比例下降,但产超广谱β-内酰胺酶肠杆菌目细菌上升,新冠疫情期间多种医院相关感染病原-药物组合的发病率与耐药均上升。
要点
- 金黄色葡萄球菌甲氧西林耐药比例从57.7%降至44.6%(AAPC -1.8%;95% CI -2.4至-1.2;p<0.0001)。
- 大肠埃希菌第三代头孢菌素耐药比例从2007年6.7%升至2019年15.3%(AAPC 8.5%;95% CI 6.2至10.7;p<0.0001)。
- 新冠疫情期间多种医院相关感染病原-药物组合的发病率与耐药均上升。
核心结论
- 金黄色葡萄球菌甲氧西林耐药、屎肠球菌万古霉素耐药及多种病原体氟喹诺酮耐药的显著下降提示防控措施对耐药产生了效果。
- 产超广谱β-内酰胺酶肠杆菌目细菌上升及近期医院相关感染激增,强调需持续监测与干预。
- 将表型发病率分析与耐药比例分析相结合可增强对耐药数据的解读。
研究设计与样本
- 美国全国回顾性队列研究,分析2007年2月1日至2022年3月31日美国138家退伍军人事务医疗中心全部急症住院患者的电子健康记录临床微生物数据。
- 共收集507760例患者的991527株30天 incident 分离株,覆盖美国50个州。
- 以每1000患者日的治疗天数(DOT)量化住院抗菌药物使用,以耐药比例和表型发病率量化耐药,采用广义估计方程模型报告年均百分比变化(AAPC)。
主要发现
- 金黄色葡萄球菌甲氧西林耐药比例从57.7%(20584株 incident 分离株中11876株)降至44.6%(13257株中5916株),AAPC -1.8%;95% CI -2.4至-1.2;p<0.0001。
- 屎肠球菌万古霉素耐药感染从77.8%(3285株中2555株)降至65.1%(1371株中893株;AAPC -1.2%;95% CI -2.5至0.0;p=0.052)。
- 氟喹诺酮类耐药在多数病原体的比例和发病率均下降,与氟喹诺酮类使用从每1000患者日125 DOT降至20 DOT相关。
- 大肠埃希菌第三代头孢菌素耐药比例从2007年6.7%(14042株中942株)升至2019年15.3%(14053株中2153株;AAPC 8.5%;95% CI 6.2至10.7;p<0.0001)。
- 阴沟肠杆菌碳青霉烯耐药比例从2007年1.1%(2852株中30株)升至2019年7.3%(2919株中212株;AAPC 19.8%;95% CI 13.7至26.2;p<0.0001),而肺炎克雷伯菌和大肠埃希菌的碳青霉烯耐药比例仍较低。
临床怎么用
- 作者认为,金黄色葡萄球菌甲氧西林耐药、屎肠球菌万古霉素耐药及多种病原体氟喹诺酮耐药的显著下降提示防控措施对耐药产生了效果。
- 作者认为,产超广谱β-内酰胺酶肠杆菌目细菌上升及近期医院相关感染激增,强调需持续监测与干预。
- 作者认为,将表型发病率分析与耐药比例分析相结合可增强对耐药数据的解读。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antimicrobial resistance poses a major threat to public health. There are few comprehensive nationwide studies that quantify long-term trends in infection incidence and antimicrobial resistance for multiple pathogens. We aimed to analyse trends in inpatient infection incidence and antimicrobial resistance for nine pathogens over the past 15 years across the USA. METHODS: In this US nationwide retrospective cohort study, we analysed clinical microbiology data from electronic health records from all patients admitted to all 138 Veterans Affairs (VA) Medical Centers with acute care wards across the USA from Feb 1, 2007, to March 31, 2022. We quantified inpatient antibiotic use as days of therapy (DOT) per 1000 patient-days and antimicrobial resistance by resistance proportion (proportion of incident isolates identified as resistant) and phenotypic incidence (incidence of infections per 1000 admissions classified as resistant, susceptible, or missing). To analyse trends before the COVID-19 pandemic and during the COVID-19 pandemic, we used generalised estimating equation models and reported average annual percentage changes (AAPC). FINDINGS: We collected 991 527 30-day incident isolates from 507 760 patients in 138 VA Medical Centers and 50 states in the USA. Between Feb 1, 2007, and Dec 31, 2019, infection incidence and antimicrobial resistance declined for many pathogens and pathogen-drug combinations. The proportion of methicillin resistance in Staphylococcus aureus decreased from 57·7% (11 876 of 20 584 incident isolates) to 44·6% (5916 of 13 257) over these 13 years (AAPC -1·8%; 95% CI -2·4 to -1·2; p<0·0001), and vancomycin-resistant Enterococcus faecium infections decreased from 77·8% (2555 of 3285) to 65·1% (893 of 1371; AAPC -1·2%; 95% CI -2·5 to 0·0; p=0·052). Fluoroquinolone resistance declined in both proportion and incidence for most pathogens. These trends correlated with substantial reductions in fluoroquinolone use, from 125 DOT per 1000 patient-days to 20 DOT per 1000 patient-days. Third generation cephalosporin resistance increased steeply in Escherichia coli infections from 6·7% (942 of 14 042) in 2007 to 15·3% (2153 of 14 053) in 2019 (AAPC 8·5%; 95% CI 6·2 to 10·7; p<0·0001). Carbapenem resistance proportion increased in Enterobacter cloacae infections from 1·1% (30 of 2852) in 2007 to 7·3% (212 of 2919) in 2019 (AAPC 19·8%; 95% CI 13·7 to 26·2; p<0·0001), but remained low for Klebsiella pneumoniae and E coli. During the COVID-19 pandemic between Jan 1, 2020, and March 31, 2022, several pathogen-drug combinations increased in both incidence and resistance for hospital-associated infections. For some pathogen-drug combinations, trends in incidence of resistant and susceptible infections were divergent, whereas for other combinations, these trends were in the same direction. INTERPRETATION: Significant reductions in methicillin resistance in S aureus, vancomycin-resistant E faecium, and fluoroquinolone resistance across multiple pathogens suggest that control efforts have had an effect on resistance. The rise in extended-spectrum β-lactamases-producing Enterobacterales and recent surge in hospital-associated infections emphasise the need for ongoing surveillance and interventions. Our study highlights how coupling the analysis of phenotypic incidence with resistance proportion can enhance interpretation of antimicrobial resistance data. FUNDING: US Centers for Disease Control and Prevention.
引用
- Pham TM, Zhang Y, Nevers M, et al. Trends in infection incidence and antimicrobial resistance in the US Veterans Affairs Healthcare System: a nationwide retrospective cohort study (2007-22). Lancet Infect Dis. 2024. PMID: 39151443. doi:10.1016/S1473-3099(24)00416-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。